Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.35 -0.10 (-0.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
A Biotech Breakout Will Be Led By Small Caps ↗
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
News headline image
NASDAQ:CPRX is showing good growth, while it is not too expensive. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
The Latest Analyst Ratings For Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
News headline image
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
News headline image
Biohaven Stock Earns Relative Strength Rating Upgrade ↗
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
News headline image
Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
NASDAQ:CPRX stands out as a growth opportunity that won't break the bank. ↗
Don't overlook CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Immunome Stock Sees RS Rating Jump To 91 ↗
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
PTC Therapeutics Stock Earns RS Rating Upgrade To 83 ↗
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. 
Via Investor's Business Daily
News headline image
Top 3 Health Care Stocks That May Crash In August ↗
 
Via Benzinga
News headline image
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You May Want To Dump This Quarter ↗
 
Via Benzinga
News headline image
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now ↗
These two healthcare stocks may be deeply undervalued. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating ↗
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.